Effect of phosphate binder on serum level of FGF23: A comparison between ferric citrate hydrate and lanthanum carbonate.

Effect of phosphate binder on serum level of FGF23: A comparison between ferric citrate hydrate and lanthanum carbonate. - Effect of phosphate binder on FGF23.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019669

Enrollment

Registered

2015-11-09

Start date

2015-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

Ferric citrate hydrate is orally administered for a month in the dose of 750 mg per day (every time after meal). It is allowed to raise its dose up to 1500 mg per day (every time after meal) for 2 mon

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD patients with hyperphosphatemia

Exclusion criteria

Exclusion criteria: Patients with iron excess

Design outcomes

Primary

Measure	Time frame
The changes of serum FGF23 levels after 1 and 3 months.	—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Dep Internal Medicine, Div Kidney and Dialysis

cherry39@hyo-med.ac.jp0798-45-6521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026